Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vanguard U.S. Momentum Factor ETF
(NY:
VFMO
)
201.30
+2.13 (+1.07%)
Official Closing Price
Updated: 8:00 PM EST, Jan 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vanguard U.S. Momentum Factor ETF
< Previous
1
2
3
Next >
Cytokinetics Wins First FDA Approval For Heart Disease Drug — Why Is Wall Street Still Cautious?
↗
December 19, 2025
The FDA approved 5 mg, 10 mg, 15 mg, 20 mg Myqorzo tablets for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
Via
Stocktwits
Lyft Draws Investor Attention After Wedbush Downgrades Stock Amid Autonomous Vehicle Risks
↗
December 19, 2025
Via
Stocktwits
Why Is CorMedix Stock Rising Today?
↗
December 18, 2025
CorMedix said that its catheter lock solution showed fewer catheter-related bloodstream infections and secondary hospitalizations in adult dialysis patients in the interim study.
Via
Stocktwits
Insmed Stock Plunges Nearly 20% After Hours As Sinus Drug Fails Mid-Stage Trial And Shows No Benefit
↗
December 17, 2025
While the drug was well tolerated with no new safety concerns, the drug yielded no positive treatment benefits in a study even at its highest dose of 40 mg.
Via
Stocktwits
JPMorgan Investment Banking Chief Plans Exit After 45 Years As Bank Ramps Up AI And Braces For $105B Costs: Report
↗
December 15, 2025
According to Grant’s Linkedin profile, he joined the lender in 1980 as an investment banker after graduating from Oxford University and rose to be the global chairman of Investment banking.
Via
Stocktwits
Topics
Artificial Intelligence
Retirement
Toll Brothers Stock Slides After-Hours On Q4 Miss And Softer Delivery Forecast
↗
December 08, 2025
Via
Stocktwits
American Eagle's Gen Z Playbook Is Working — Sydney Sweeney And Travis Kelce Might Only Be The Opening Act
↗
December 03, 2025
Via
Stocktwits
Uber In Talks With Getir To Expand Delivery Services In Turkey: Report
↗
November 06, 2025
Via
Stocktwits
Palantir CIO Jim Siders To Depart After 12 Years To Head Thrive Capital’s New IT Services Business
↗
December 15, 2025
im Siders said that Shield has an incredible combination of long-term vision, technological expertise, and operational know-how, making it perfect for him at the moment.
Via
Stocktwits
Topics
Artificial Intelligence
ServiceNow Stock Is Down 5% Today — What’s Weighing On The Shares?
↗
December 15, 2025
KeyBank downgraded ServiceNow to ‘Underweight’ from ‘Sector Weight’ with a price target of $775.
Via
Stocktwits
Topics
Artificial Intelligence
Broadcom Stock Jumps After Hours As Strong Q4 And Surging AI Chip Demand Drive Upbeat Outlook
↗
December 11, 2025
The company now expects $19.1 billion in sales in the first quarter of fiscal year 2026, above an analyst estimate of $18.3 billion on the back of strong AI chip demand.
Via
Stocktwits
Topics
Artificial Intelligence
Rhythm Pharmaceuticals Stock Rises After Positive Study Data For Setmelanotide In Treating Genetic Disorder
↗
December 11, 2025
The company was studying the therapy in Prader-Willi Syndrome, a rare genetic disorder requiring lifelong management.
Via
Stocktwits
BHVN Stock Tumbled A Whopping 44% Today – What Did The FDA Letter Say?
↗
November 05, 2025
Via
Stocktwits
Carvana Stock In Spotlight After 6% Slide Today: BTIG Maintains ‘Buy’ Rating
↗
October 17, 2025
Via
Stocktwits
Jefferies CEO Claims Bank Was ‘Defrauded’ By Bankrupt Auto Supplier First Brands Group
↗
October 17, 2025
Via
Stocktwits
Topics
Bankruptcy
Supply Chain
Micron To Stop Selling Crucial Consumer Products As It Heightens Focus On Larger Customers
↗
December 03, 2025
The company said that it will continue to ship Crucial products to consumers through the end of February 2026.
Via
Stocktwits
Abercrombie & Fitch Catches Retail Attention After Barclays Raises Price Target On Hollister Momentum
↗
November 28, 2025
Barclays raised its price target on Abercrombie & Fitch to $94 from $84 and maintained an ‘Equal Weight’ rating, according to TheFly.
Via
Stocktwits
Why ANF Stock Is Soaring Before The Bell Today?
↗
November 25, 2025
Abercrombie now expects net sales to grow in the range of 6% to 7% for fiscal year 2025, compared with the prior forecast of 5% to 7% rise.
Via
Stocktwits
Micron Stock Draws Investor Attention Following A Price Target Boost From UBS
↗
November 20, 2025
UBS maintained a ‘Buy’ rating on the shares and noted that its recent channel checks indicate "tight" supply conditions persist.
Via
Stocktwits
AGIO Stock Cracks After Sickle-Cell Disease Drug Delivers Mixed Results In Late-Stage Trial
↗
November 19, 2025
While Mitapivat also showed a reduction in the primary endpoint of annualized rate of sickle cell pain crises (SCPCs) compared to placebo, this trend did not achieve statistical significance, Agios...
Via
Stocktwits
OLMA Stock Doubles After Roche Cancer Drug Trial Yields Positive Results
↗
November 18, 2025
Roche was evaluating Giredestrant as an adjuvant endocrine treatment for people with certain types of early-stage breast cancer.
Via
Stocktwits
Why Did Scholar Rock Soar 26% Today?
↗
November 14, 2025
The company is planning to reapply for approval of a muscle atrophy therapy in the coming year.
Via
Stocktwits
Topics
Earnings
Uber COO Says Robotaxi Tech Is Largely Ready But Hardware Costs Are Still Too High
↗
November 12, 2025
Uber has partnerships in place with multiple robotaxi companies, including Pony AI, WeRide and Alphabet Inc’s Waymo.
Via
Stocktwits
Topics
Artificial Intelligence
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance
↗
November 12, 2025
The company now expects pro forma net revenue for the full year in a range of $390 million to $410 million, higher than a Wall Street estimate of $283.66 million.
Via
Stocktwits
Topics
Earnings
2 Vanguard ETFs to Buy Hand Over Fist and 1 to Avoid
↗
November 12, 2025
Low-cost ETFs are excellent ways to build a diversified stock portfolio without incurring high fees.
Via
The Motley Fool
Topics
ETFs
Fiserv Shares Plunge 44% In Record One-Day Drop As Company Gets Wall Street Downgrades On Leadership Changes, Forecast Cuts
↗
October 29, 2025
Wolfe Research downgraded Fiserv to ‘Peer Perform’ from ‘Outperform,’ according to TheFly, on the heels of the guidance cut that it says "raised structural concerns."
Via
Stocktwits
BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results
↗
October 29, 2025
76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment.
Via
Stocktwits
Fiserv Stock Plunges 32% As New CFO Paul Todd Steps In Amid Leadership Overhaul, Profit Warning
↗
October 29, 2025
Fiserv now expects 2025 adjusted earnings per share to come between $8.50 and $8.60, down from the previous forecast of $10.15 to $10.30.
Via
Stocktwits
Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy
↗
October 23, 2025
CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months.
Via
Stocktwits
Arcturus Therapeutics Stock Plunges Over 57% Today: What’s Causing The Sell-Off?
↗
October 22, 2025
The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing.
Via
Stocktwits
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit